BOARD OF DIRECTORS

Upon [**REDACTED**], our Board will consist of seven Directors, with four executive Directors and three independent non-executive Directors. Our Board serves a term of three years and is responsible for, and has general powers for, the management and conduct of our business.

The table below sets out certain information in respect of the members of our Board.

Name	Age	Position	Date of appointment as Director	Date of joining our Group	Role and responsibilities	Relationship with other Directors and senior management
Executive Directors						
Dr. ZHANG Shaodian (張少典) . . .	37	Chairperson of our Board, executive Director, founder and chief executive officer	April 25, 2016	April 25, 2016	Responsible for overall strategic planning, business direction, corporate management and innovation strategy of our Group	None
Dr. MA Handong (馬漢東) . . .	35	Executive Director, co-founder and general manager of East China region	January 19, 2017	April 25, 2016	Responsible for sales, delivery, and customer service in the East China region and Asia-Pacific Region, and major strategic clients of our Group	None
Mr. YIN Jiaheng (殷嘉珩) . . .	34	Executive Director, co-founder and chief technology officer	June 13, 2022	April 25, 2016	Responsible for core technology research and development, technical team management and product development planning of our Group	None
Mr. TIAN Mutong (田牧童) . . .	31	Executive Director and Board secretary	September 6, 2025	May 18, 2023	Responsible for corporate governance, board administration and investor communication of our Group	None

Name	Age	Position	Date of appointment as Director	Date of joining our Group	Role and responsibilities	Relationship with other Directors and senior management
Independent Non-executive Directors						
Ms. WONG Yan Ki Angel (黃欣琪) . . .	54	Independent Non-executive Director	September 24, 2025 (effective from [REDACTED])	September 24, 2025 (effective from [REDACTED])	Responsible for providing independent advice and judgment to our Board	None
Dr. ZHOU Dongsheng (周東生) . . .	58	Independent Non-executive Director	September 24, 2025 (effective from [REDACTED])	September 24, 2025 (effective from [REDACTED])	Responsible for providing independent advice and judgment to our Board	None
Dr. ZHANG Weinan (張偉楠) . . .	37	Independent Non-executive Director	September 24, 2025 (effective from [REDACTED])	September 24, 2025 (effective from [REDACTED])	Responsible for providing independent advice and judgment to our Board	None

Note: As of the Latest Practicable Date, Mr. ZHU Feng (朱峰) and Mr. ZHAI Jia (翟佳) are our non-executive Directors appointed by two of our investors. Both will resign from directorship, effective before [**REDACTED**].

Executive Directors

Dr. ZHANG Shaodian (張少典), aged 37, is the chairperson of our Board, an executive Director, founder and the chief executive officer of our Company. Dr. Zhang founded our Group in April 2016, and has been serving as a Director and the chief executive officer of our Company since then. Dr. Zhang has served as a Director since April 25, 2016 and was re-designated as an executive Director on September 24, 2025. Dr. Zhang is primarily responsible for overall strategic planning, business direction, corporate management and innovation strategy of our Group. Dr. Zhang has also served as a director of Yilianwang since July 14, 2022, and as a director of Mukang since July 21, 2022.

Dr. Zhang is a leading medical informatics expert that has published 31 research papers with more than 1,900 citations in the field of medical informatics and healthcare AI. In recent years, Dr. Zhang has led his team in undertaking over ten national and provincial research projects, including ones sponsored by the National Key R&D Program and the National Natural Science Foundation of China (NSFC). Dr. Zhang has obtained 12 patents, including seven as the first inventor, many of which have generated significant economic and social benefits.

Dr. Zhang is currently a vice chairman of the Internet Hospital Professional Committee of the Chinese Health Information and Big Data Association (中國衛生信息與健康醫療大數據學會互聯網醫院專業委員會), an executive member of the first session of the Smart Hospital and Artificial Intelligence Application Working Committee of the Chinese Health Information and Big Data Association (中國衛生信息與健康醫療大數據學會智慧醫院與人工智能應用工作委員會), a member of the Clinical Research Expert Committee of the Clinical Research Promotion and Development Center of Shanghai Shenkang Hospital Development Center (上海申康醫院發展中心市級醫院臨床研究促進發展中心"臨床研究專家委員會"), a member of the Health Informatics Education Professional Committee of the Chinese Health Information and Big Data Association (中國衛生信息與健康醫療大數據學會衛生信息學教育專業委員會), and an advisor to the Pediatrics Professional Committee of the Chinese Health Information and Big Data Association (中國衛生信息與健康醫療大數據學會兒科專業委員會).

Dr. Zhang obtained various awards during his professional career, including being recognized as a Shanghai Pujiang Talent (上海市浦江人才), a Shanghai Overseas High-level Talent (上海市海外高層次引進人才), and one of the Top 10 Outstanding Young Entrepreneurs in Pudong New Area (浦東新區十大優秀青年企業家). In addition, Dr. Zhang was named to the Forbes Asia 30 Under 30 List in 2017 (Healthcare & Science), the Hurun China 30 Under 30 Entrepreneurial Leaders in 2017, Fortune's 40 Under 40 Business Leader, and Forbes' China 100 Young Returned Elites.

Dr. Zhang obtained his bachelor's degree in computer science from Shanghai Jiao Tong University (上海交通大學) in the PRC in July 2011, and further obtained his Ph.D. of biomedical informatics from Columbia University in the United States in May 2016. He has been certified as a professor-level senior engineer (正高級工程師) by the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in February 2025.

Dr. MA Handong (馬漢東), aged 35, is an executive Director, co-founder and the general manager of East China region of our Company. Dr. Ma co-founded our Group in April 2016 and has been serving as the general manager of East China region since then. Dr. Ma was appointed as a Director on January 19, 2017 and was re-designated as an executive Director on September 24, 2025. Dr. Ma is primarily responsible for sales, delivery, and customer service in the East China region (the largest business area of our Group) and Asia-Pacific Region, and major strategic clients of our Group. Dr. Ma has also served as a director of Yilianwang since July 14, 2022.

Dr. Ma has extensive experience in biomedical informatics, computer science, and sales management. In recent years, Dr. Ma has led and participated in several national and provincial level research projects, while also contributing as an editorial board member to the development of the Standardized Dataset for VTE and the Standardized Dataset for Brain-Heart Comorbidities. Dr. Ma has published 17 international journal and conference papers, including 13 as first or corresponding author, and has obtained ten patents, with seven as first inventor. Dr. Ma was listed in the Hurun U30 China Entrepreneurial Leaders (2021) and the Forbes China 30 Under 30 List (2018). In 2020, Dr. Ma was selected for the Shanghai Youth Science and Technology Talent Sailing Program (上海市青年科技英才揚帆計劃). Dr. Ma was recognized by the Pudong New Area governmental authorities of Shanghai as a Pearl Leading Talent (明珠領軍人才) in November 2025.

Dr. Ma obtained his bachelor's degree in biology from Fudan University (復旦大學) in the PRC in July 2013, and his master's degree in biomedical informatics at Columbia University in the United States in June 2015. He further obtained his doctor's degree in computer science and technology from Shanghai Jiao Tong University (上海交通大學) in the PRC in September 2022, on a part-time basis while concurrently engaged in his professional duties. Dr. Ma has been certified as a professor-level senior engineer (正高級工程師) by the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in February 2025.

Mr. YIN Jiaheng (殷嘉珩), aged 34, is an executive Director, co-founder and the chief technology officer of our Company. Mr. Yin co-founded our Group in April 2016 and has been serving as the chief technology officer since then. Mr. Yin was a Director from July 6, 2017 to December 7, 2020. He was re-appointed as a Director on June 13, 2022 and was re-designated as an executive Director on September 24, 2025. Mr. Yin is primarily responsible for core technology research and development, technical team management and product development planning of our Group.

Mr. Yin has a solid background in technology research and development and technical team management. He pursued doctoral studies as a fully funded Ph.D. candidate at Georgia State University in the United States in August 2015. Since co-founding our Group, he has been responsible for leading the core technology R&D and overseeing the construction and management of the technical team. Mr. Yin was recognized by the People's Government of Pudong New Area, Shanghai, as a Pearl Engineer (明珠工程師) in December 2023 and as a Pearl Elite Talent (明珠菁英人才) in June 2025. Mr. Yin has been certified as a senior engineer by the Shanghai Municipal Human Resources and Social Security Bureau in December 2025.

Mr. Yin obtained his bachelor's degree in biological sciences from Fudan University (復旦大學) in the PRC in June 2014. Mr. Yin has been certified as a senior artificial intelligence trainer (高級人工智能訓練師) by the Shanghai Artificial Intelligence Industry Association (上海市人工智能行業協會) in August 2022.

Mr. TIAN Mutong (田牧童), aged 31, is an executive Director and the Board secretary of our Company. Mr. Tian joined our Group in May 2023 and has been serving as the Board secretary since then. Mr. Tian was appointed as a Director on September 6, 2025 and was re-designated as an executive Director on September 24, 2025. Mr. Tian is primarily responsible for corporate governance, board administration and investor communication of our Group. Mr. Tian has served as a director of Yilianwang since November 14, 2025.

Mr. Tian possesses solid experience in finance, investment and corporate management. Prior to joining our Group, Mr. Tian served as assistant to the general manager and head of financing at Shanghai Thoven Intelligent Technology Co., Ltd. (上海特霍芬智能科技有限公司), which is principally engaged in the development of intelligent technology solutions, from January 2022 to January 2023, where he was primarily responsible for the company's initial establishment, equity financing and strategic execution. From October 2019 to November 2020, he served as investment director at Shanghai Yaozhi Wanhua Enterprise Development Co., Ltd. (上海耀之萬華企業發展有限公司), which is principally engaged in financial, management, and information consulting, where he was primarily responsible for equity investment. From September 2018 to September 2019, he served as investment manager at Hangzhou O_2 Investment Management Co., Ltd. (杭州氧氣投資管理有限公司), which is principally engaged in investment management. From June 2017 to July 2018, he worked at Naked Hotel Management (Shanghai) Co., Ltd. (裸心酒店管理(上海)有限公司), which is principally engaged in hotel design, development, and management.

Mr. Tian obtained his bachelor's degree in finance from New York University Shanghai (上海紐約大學) in the PRC in May 2017.

Independent Non-executive Directors

Ms. WONG Yan Ki Angel (黃欣琪), aged 54, was appointed as an independent non-executive Director of our Company on September 24, 2025 with effect upon the [**REDACTED**]. Ms. Wong will be responsible for providing independent professional opinion and judgement to the Board.

Ms. Wong has 30 years of experience in accounting, auditing, corporate finance and capital market. Ms. Wong joined Kwan Wong Tan & Fong in October 1995, which later merged with Deloitte Touché Tohmatsu in August 1997, and resigned from Deloitte Touché Tohmatsu in November 1999. She later served a number of roles at Great East Packaging Holdings Limited (偉東包裝製品集團有限公司), which is principally engaged in the manufacturing and sale of packaging products, from October 1999 to March 2003, including group financial controller and assistant finance manager. Between April 2003 and December 2007, she held various positions at Benefit Capital Limited (百富達融資有限公司), which is primarily engaged in providing IPO consulting services, including vice president and executive director. From April 2005 to November 2005, she also acted as chief financial officer of Shengda (Group) Holdings Ltd (勝達國際控股有限公司), which is engaged in the production and manufacturing of corrugated paper packaging. Since November 2007, Ms. Wong has been an executive director of Advanced Capital Limited (匯財資本有限公司), which is principally engaged in corporate advisory services, where she is responsible for operation management and major decisions.

Currently, Ms. Wong is an independent non-executive director in (i) Betta Pharmaceuticals Co., Ltd. (貝達藥業股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300558), since January 2021; and (ii) Henan Jinyuan Hydrogenated Chemicals Co., Ltd. (河南金源氫化化工股份有限公司), a company listed on the Stock Exchange (stock code: 2502), since October 2023, and (iii) ALPHAMAB ONCOLOGY (康寧傑瑞生物製藥) a company listed on the Stock Exchange (stock code: 9966), since June 2025, respectively.

Previously, Ms. Wong also held directorships in various public companies listed in different countries and regions. From August 2009 to January 2011, she served as a non-executive director of Esmart Holdings Limited (currently known as Duty Free International Limited), a company listed on The Stock Exchange of Singapore Dealing and Automated Quotation System (stock code: DutyFree), during which she acted as the chairlady of the board from February 2010 to January 2011. Ms. Wong served as an independent non-executive director of the below companies:

(i) China Best Group Holding Limited (國華集團控股有限公司) (currently known as Hong Kong Robotics Group Holding Limited (港仔機器人集團控股有限公司), a company listed on the Stock Exchange (stock code: 0370), from June 2011 to September 2014;

(ii) Oriental Unicorn Agricultural Group Limited (東麟農業集團有限公司) (currently known as China Demeter Financial Investments Limited (國農金融投資有限公司)), a company listed on the GEM of the Stock Exchange (stock code: 8120), from October 2011 to May 2013;

(iii) Hengxing Gold Holding Company Limited (恆興黃金控股有限公司), a company listed on the Stock Exchange (stock code: 2303, which was privatized and delisted in February 2021), from March 2013 to February 2021;

(iv) China Shengda Packaging Group Inc. (中國勝達包裝集團有限公司), a company listed on the Nasdaq Stock Exchange (stock code: CPGI, which was privatized and delisted in September 2015), from August 2014 to September 2015;

(v) BIT Mining Limited (formerly known as 500.com Limited), a company listed on the New York Stock Exchange (stock code: BTCM), from November 2015 to April 2023;

(vi) China Public Procurement Limited (中國公共採購有限公司) (currently known as Cherish Sunshine International Limited (承輝國際有限公司)), a company listed on the Stock Exchange (stock code: 1094), from December 2015 to July 2018;

(vii) Yuhua Energy Holdings Limited (裕華能源控股有限公司) (currently known as Jintai Energy Holdings Limited (金泰能源控股有限公司)), a company listed on the Stock Exchange (stock code: 2728), from November 2016 to December 2018;

(viii) Miko International Holdings Limited (米格國際控股有限公司), a company listed on the Stock Exchange (stock code: 1247), from July 2017 to July 2018;

(ix) Many Idea Cloud Holdings Limited (多想雲控股有限公司), a company listed on the Stock Exchange (stock code: 6696), from October 2022 to June 2025; and

(x) Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. (國鴻氫能科技(嘉興)股份有限公司), a company listed on the Stock Exchange (stock code: 9663), from October 2022 to May 2026, respectively.

Ms. Wong obtained a bachelor of economics in international accounting, from Xiamen University (廈門大學) in the PRC in July 1994, a post-graduate certificate in professional accounting from the City University of Hong Kong in November 2000 and an executive master degree of business administration from Cheung Kong Graduate School of Business (長江商學院) in the PRC in October 2009. Ms. Wong obtained the certificates of follow-up training courses for independent directors of listed companies from the Shenzhen Stock Exchange in May 2022 and August 2024, and also obtained the pre-appointment training certificate for STAR Market independent directors from the Shanghai Stock Exchange in April 2023. Ms. Wong has been admitted as a member or fellow member of several associations. Ms. Wong has been successively admitted as a fellow member of the Institute of Financial Accountants in the United Kingdom (IFA) (英國財務會計師公會) since October 2003, fellow member of the Society of Registered Financial Planners in Hong Kong (HKRFP) (註冊財務策劃師協會) since November 2003, member of the Hong Kong Institute of Directors (HKIoD) (香港董事學會) since November 2014 and admitted as a Fellow in November 2025, fellow member of the Institute of Public Accountants (FIPA) (澳洲公

共會計師協會資深會員) since April 2015, founding member of the Hong Kong Independent Non-executive Director Association (HKiNEDA) (香港獨立非執行董事協會) since January 2016, fellow member of CPA Australia (FCPA Aust.) (澳洲會計師公會) since May 2017, member of the Guangdong Association of Management Accountants (廣東省管理會計師協會) since December 2017, member of the Association of Chinese Internal Auditors in Hong Kong (ACIA) (香港華人內部審計師公會) since April 2022 and became a Certified Chinese Internal Auditor in July 2025, and fellow member of the Institute of Certified Management Accountant (CMA Aust.) (澳大利亞註冊管理會計師協會) since June 2024, respectively.

Dr. ZHOU Dongsheng (周東生), aged 58, was appointed as an independent non-executive Director of our Company on September 24, 2025 with effect upon the [**REDACTED**]. Dr. Zhou will be responsible for providing independent professional opinion and judgement to the Board.

Dr. Zhou has more than 26 years of experience in management science, marketing, and higher education. Dr. Zhou has been serving as a professor of marketing since September 2002 and is also currently the director of the CEIBS Healthcare Sector Research Centre at China Europe International Business School (中歐國際工商學院), where he is primarily responsible for teaching, research, and academic leadership in marketing and health care management. From June 1997 to August 2002, he served as assistant professor and associate professor at City University of Hong Kong (香港城市大學). Since May 2023, Dr. Zhou has been serving as an independent director of Giant Network Group Co., Ltd (巨人網絡集團股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002558). From September 2019 to September 2024, Dr. Zhou served as an independent director of Beijing Hanyi Innovation Technology Co., Ltd (北京漢儀創新科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301270). From July 2018 to May 2025, Dr. Zhou served as an independent director of Cango Inc., a company listed on the New York Stock Exchange (stock code: CANG).

Dr. Zhou obtained his bachelor's degree in science and technology management from University of Science and Technology of China (中國科學技術大學) in the PRC in June 1990, and further obtained his doctor's degree in management science from the University of British Columbia in Canada in May 1997.

Dr. ZHANG Weinan (張偉楠), aged 37, was appointed as an independent non-executive Director of our Company on September 24, 2025 with effect upon the [**REDACTED**]. Dr. Zhang will be responsible for providing independent professional opinion and judgement to the Board.

Dr. Zhang is highly experienced in computer science and artificial intelligence research and education. Since August 2016, Dr. Zhang has been serving as a professor at the Department of Computer Science, Shanghai Jiao Tong University (上海交通大學), where he is primarily responsible for teaching and research in the field of artificial intelligence.

Dr. Zhang obtained his bachelor's degree in computer science and technology from Shanghai Jiao Tong University (上海交通大學) in the PRC in July 2011, and further obtained his doctor's degree in computer science from University College London in the United Kingdom in June 2016.

General

Save as disclosed in this section and the section headed "Statutory and General Information" in Appendix IV to this document, each of our Directors has confirmed that:

(1) he/she has obtained legal advice referred to under Rule 3.09D of the Listing Rules on September 18, 2025 and understood his/her obligations as a director of a [**REDACTED**] under the Listing Rules and the possible consequences of making a false declaration or giving false information to the Stock Exchange;

(2) as of the Latest Practicable Date, he/she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules;

(3) he/she does not have any existing or proposed service contract with our Company or any of its subsidiaries other than contracts expiring or determinable by the relevant member of our Company within one year without payment of compensation (other than statutory compensation);

(4) he/she does not have any interests in the Shares within the meaning of Part XV of the SFO;

(5) he/she has not been a director of any other publicly listed company during the three years prior to the Latest Practicable Date and as of the Latest Practicable Date;

(6) other than being a Director of our Company, he/she does not have any relationship with any other Directors and senior management of our Company or substantial shareholders of our Company; and

(7) he/she has not completed his/her education programs as disclosed in this section by way of attendance of long distance learning or online courses.

Each of our independent non-executive Directors has confirmed:

(1) his/her independence after taking into consideration each of the factors referred to under Rules 3.13(1) to 3.13(8) of the Listing Rules;

(2) that he/she does not have any past or present financial or other interest in the business of our Company or our subsidiaries, or any connection with any core connected person of our Company; and

(3) that there are no other factors which may affect his/her independence at the time of his/her appointment as our independent non-executive Director.

Save as disclosed in this document, to the best of the knowledge, information and belief of our Directors having made all reasonable enquiries:

(1) there is no other matter with respect to the appointment of our Directors that needs to be brought to the attention to the Shareholders as of the Latest Practicable Date; and

(2) there is no other information relating to our Directors that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules as of the Latest Practicable Date.

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management and operation of our business. The table below sets out certain information in respect of the senior management of our Company.

Name	Age	Position	Date of appointment as senior management	Date of joining our Group	Role and responsibilities	Relationship with Directors and other senior management
Dr. ZHANG Shaodian (張少典) . . .	37	Chairperson of our Board, executive Director, founder and chief executive officer	April 25, 2016	April 25, 2016	Responsible for overall strategic planning, business direction, corporate management and innovation strategy of our Group	None

Name	Age	Position	Date of appointment as senior management	Date of joining our Group	Role and responsibilities	Relationship with Directors and other senior management
Dr. MA Handong (馬漢東). . .	35	Executive Director, co-founder and general manager of East China region	April 25, 2016	April 25, 2016	Responsible for sales, delivery, and customer service in the East China region and Asia-Pacific Region and major strategic clients of our Group	None
Mr. YIN Jiaheng (殷嘉珩). . .	34	Executive Director, co-founder and chief technology officer	April 25, 2016	April 25, 2016	Responsible for core technology research and development, technical team management and product development planning of our Group	None
Mr. TIAN Mutong (田牧童). . .	31	Executive Director and Board secretary	May 18, 2023	May 18, 2023	Responsible for corporate governance, board administration and investor communication of our Group	None
Mr. ZHANG Zhenzhong (張振忠). . .	39	Chief financial officer	March 8, 2021	March 8, 2021	Responsible for financial management, business-finance integration, and capital planning of our Group	None

Dr. ZHANG Shaodian (張少典), see "— Board of Directors — Executive Directors" in this section for his biographical details.

Dr. MA Handong (馬漢東), see "— Board of Directors — Executive Directors" in this section for his biographical details.

Mr. YIN Jiaheng (殷嘉珩), see "— Board of Directors — Executive Directors" in this section for his biographical details.

Mr. TIAN Mutong (田牧童), see "— Board of Directors — Executive Directors" in this section for his biographical details.

Mr. ZHANG Zhenzhong (張振忠), aged 39, is the chief financial officer of our Company. Mr. Zhang joined our Group in March 2021 as the senior finance manager and was appointed as the chief financial officer on March 28, 2025. Mr. Zhang is primarily responsible for financial management, business-finance integration, and capital planning of our Group.

Mr. Zhang possesses extensive practical experience in financial management and corporate finance across various sectors. Prior to joining our Group, Mr. Zhang served as budget manager at Wanxiang Group Tonglian Data Co., Ltd. (萬向集團通聯數據股份公司), which is principally engaged in information data services, from May 2020 to March 2021, where he was primarily responsible for organizing the preparation of annual budget plans, setting budget targets using financial models, and improving budget accuracy through dynamic adjustment mechanisms. From October 2019 to April 2020, he served as general ledger supervisor at Ouyou Hotel Management (Shanghai) Co., Ltd. (鷗游酒店管理(上海)有限公司), which is principally engaged in hotel management, where he was responsible for establishing accounting standards and financial management systems, reconciling general and subsidiary ledgers, and managing monthly closing and accounting periods. From May 2015 to April 2019, he served as finance manager and assistant to the general manager at Russian Luxipjan Mining Company (俄羅斯陸西普詹姆礦業公司), which is principally engaged in mining operations, where he was responsible for preparing PRC financial statements and financial analysis.

Mr. Zhang obtained his bachelor's degree in business administration from North China Electric Power University (華北電力大學) in the PRC in July 2010, and further obtained his master's degree in international marketing and management from Saint Petersburg State Technological University in Russia in June 2014. Mr. Zhang obtained the qualification of asset valuer issued by the China Appraisal Society (中國資產評估協會) in September 2020, and obtained the qualification of intermediate accountant issued by the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部) and the Ministry of Finance of the PRC (中華人民共和國財政部) in September 2020.

General

Save as disclosed in this section, each of our senior management members has confirmed that:

(1) he does not hold and has not held any other positions in our Company and any other members of our Company as of the Latest Practicable Date;

(2) other than being a Director and/or a member of our Company's senior management, he does not have any relationship with any Directors and any other senior management members of our Company or substantial shareholders of our Company;

(3) he has not been a director of any other publicly listed company during the three years prior to the Latest Practicable Date and as of the Latest Practicable Date; and

(4) he has not completed his education programs as disclosed in this section by way of attendance of long distance learning or online courses.

JOINT COMPANY SECRETARIES

Mr. TIAN Mutong (田牧童) was appointed as one of our joint company secretaries on September 24, 2025, see "— Board of Directors — Executive Directors" in this section for his biographical details.

Mr. POON Ping Yeung (潘秉揚) was appointed as one of our joint company secretaries on September 24, 2025. Mr. Poon is the senior manager of the listed & fiduciary corporate services of Trident Corporate Services (Asia) Ltd., a global professional services firm. He has over 10 years of professional experience in company secretarial field. He is currently a joint company secretary of each of Boyaa Interactive International Limited (a company listed on the Stock Exchange (stock code: 434)), Shanghai REFIRE Group Limited (a company listed on the Stock Exchange (stock code: 2570)) and Zhejiang Taimei Medical Technology Co., Ltd. (a company listed on the Stock Exchange (stock code: 2576)).

Mr. Poon obtained his bachelor's degree in arts (major in social policy and administration) from The Hong Kong Polytechnic University in Hong Kong in October 2012. He further obtained his master's degree in corporate governance from Hong Kong Metropolitan University (formerly known as The Open University of Hong Kong) in Hong Kong in October 2019.

Mr. Poon is an associate member (a holder of practitioner's endorsement) of The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) in the United Kingdom.

COMPLIANCE ADVISER

We have appointed Patrons Capital Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, the compliance adviser will advise us on the following circumstances:

- before the publication of any announcements, circulars or financial reports;
- where a transaction, which might be a notifiable or connected transaction under Chapters 14 and 14A of the Listing Rules is contemplated, including share issues, sales or transfers of treasury shares and share repurchases;
- where we propose to use the [**REDACTED**] of the [**REDACTED**] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and
- where the [**REDACTED**] makes an inquiry of us regarding unusual [**REDACTED**] and [**REDACTED**] or other issues under Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, Patrons Capital Limited will, in a timely manner, inform us of any amendment or supplement to the Listing Rules and new or amended laws and regulations in Hong Kong applicable to us.

The terms of the appointment shall commence on the [**REDACTED**] and end on the date which we distribute our annual report of our financial results for the first full financial year commencing after the [**REDACTED**].

BOARD COMMITTEES

We have established the following committees on our Board: the Audit Committee, the Remuneration and Appraisal Committee and the Nomination Committee (effective from the [**REDACTED**]). The committees operate in accordance with the terms of reference established by our Board.

Audit Committee

The Company has established the Audit Committee (effective from the [**REDACTED**]) with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph C.4 and paragraph D.3 of Part 2 of the Corporate Governance Code. The Audit Committee consists of three Directors, namely Ms. WONG Yan Ki Angel (黃欣琪), Dr. ZHOU Dongsheng (周東生) and Dr. ZHANG Weinan (張偉楠), with Ms. WONG, Yan Ki Angel (黃欣琪) serving as the chairperson. Ms. WONG Yan Ki Angel (黃欣琪) holds the appropriate professional qualifications and accounting or related financial management expertise as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee include, but not limited to, the following:

- proposing the appointment or change of external auditors to the Board, and monitoring the independence of external auditors and evaluating their performance;
- examining the financial information of our Company and reviewing financial reports and statements of our Company;
- examining the financial reporting system, the risk management and internal control system of our Company, overseeing their rationality, efficiency and implementation and making recommendations to the Board; and
- dealing with other matters that are authorized by the Board.

Remuneration and Appraisal Committee

Our Company has established the Remuneration and Appraisal Committee (effective from the [**REDACTED**]) with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph E.1 of the Corporate Governance Code. The Remuneration Committee consists of three Directors, namely Dr. ZHANG Weinan (張偉楠), Dr. ZHANG Shaodian (張少典) and Dr. ZHOU Dongsheng (周東生), with Dr. ZHANG Weinan (張偉楠) serving as the chairperson. The primary duties of the Remuneration Committee include, but not limited to, the following:

- advising the Board on the overall remuneration plan and structure of Directors and senior management and the establishment of transparent formal procedures for determining remuneration policy of our Company;
- examining the criteria of performance evaluation of Directors and the senior management of our Company, conducting performance evaluation and making recommendations to the Board;
- formulating individual remuneration plans for Directors and members of the senior management in accordance with the terms of reference of the importance of their positions, the time they spend on such positions as well as the remuneration benchmarks for the relevant positions in the other comparable companies; and
- dealing with other matters that are authorized by the Board, and if necessary, engaging external experts to provide relevant independent services.

Nomination Committee

Our Company has established the Nomination Committee (effective from the [**REDACTED**]) with written terms of reference in compliance with paragraph B.3 of the Corporate Governance Code. The Nomination Committee consists of three Directors, namely Dr. ZHANG Shaodian (張少典), Ms. WONG Yan Ki Angel (黃欣琪) and Dr. ZHANG Weinan (張偉楠), with Dr. ZHANG Shaodian (張少典) serving as the chairperson. The primary functions of the Nomination Committee include, but not limited to, the following:

- conducting extensive search and providing to the Board suitable candidates for Directors, general managers and other members of the senior management;
- overseeing the implementation of Board diversity policy; taking into account various factors when determining the composition of the Board, including, but not limited to, gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and service tenure;
- examining the size and composition of the Board and its members in respect of their skills, knowledge, experience and diversity at least once every year, and making recommendations to the Board on any change in Board composition in accordance with our Company's strategies;
- researching and developing standards and procedures for the election of the Board members, general managers and members of the senior management, and making recommendations to the Board; and
- dealing with other matters that are authorized by the Board.

CORPORATE GOVERNANCE

Corporate Governance Code

We recognize the importance of good corporate governance and are committed to maintaining high standards in our management structure and internal control procedures. Our Company intends to comply with all code provisions set out in Part 2 of the Corporate Governance Code in Appendix C1 to the Listing Rules after the [**REDACTED**], except for code provision C.2.1, which stipulates that the roles of chairman of the board and chief executive should be separate and should not be performed by the same individual.

Currently, the roles of chairman of the Board and chief executive officer of our Company are both performed by Dr. Zhang. Dr. Zhang is the founder of our Group and has been instrumental in our growth and business expansion since inception. The Board believes that vesting the roles of chairman and chief executive officer in Dr. Zhang is beneficial to the management of the Company and will provide strong and consistent leadership, facilitating the efficient execution of our business strategies. The Board therefore currently does not propose to separate the roles of chairman and chief executive officer.

While this constitutes a deviation from code provision C.2.1 of the Corporate Governance Code, the Board believes that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (i) there are sufficient checks and balances in the Board, as decisions require approval by at least a majority of the Directors, and the Board comprises three independent non-executive Directors, in compliance with the Listing Rules; (ii) Dr. Zhang and the other Directors are aware of and undertake to fulfill their fiduciary duties as Directors, which require, among other things, that they act for the benefit and in the best interests of the Company and make decisions accordingly; (iii) the balance of power and authority is ensured by the operation of the Board, which comprises experienced and high-caliber individuals who meet from time to time to discuss issues affecting the Company's operations; and (iv) the overall strategic and other key business, financial, and operational policies of the Company are made collectively after thorough discussion at both Board and senior management levels. The Board will continue to review the effectiveness of the corporate governance structure of the Company to assess whether the separation of the roles of chairman and chief executive officer is necessary.

Board Diversity

We [have] adopted a board diversity policy (the "**Board Diversity Policy**") to enhance the effectiveness of our Board and to maintain a high standard of corporate governance. Pursuant to the Board Diversity Policy, in reviewing and assessing suitable candidates to serve as a Director, the Nomination Committee will consider a range of diversity perspectives with reference to our Company's business model and specific needs, including but not limited to gender, age, language, cultural and educational background, professional qualifications, skills, knowledge, industry and regional experience and/or length of service.

Our Directors collectively bring a wide spectrum of professional knowledge, experience and perspectives to the Board. Their combined expertise spans corporate strategy and general management, healthcare and biomedical informatics, artificial intelligence and information technology research and development, sales and marketing, investment and capital markets, accounting and finance, and tertiary-level teaching and academic research. Academically, they hold bachelor's, master's and doctoral degrees in computer science and technology, biomedical informatics, biological sciences, finance, metal forming technology and materials engineering, economics, accounting, business administration, science and technology management and management science, among others. The breadth and depth of these competencies enable the Board to exercise effective oversight and provide well-rounded guidance for the Group's sustainable growth. We are firmly committed to fostering gender diversity at the Board and throughout the organisation. Upon [**REDACTED**], our Board will comprise one female Director and six male Directors. The Nomination Committee will continue to identify and consider qualified female candidates in future board succession planning so as to further enhance gender balance. Our Directors also represent a healthy range of ages, from 31 to 58 years old, striking a balance between fresh viewpoints and extensive industry experience. Taking into account the diversity of gender, age, professional background, skills and academic qualifications described above, the Board is satisfied that its present composition is consistent with, and gives full effect to, the Company's Board Diversity Policy.

The Board of Directors is of the view that the Board satisfies the Board Diversity Policy. The Nomination Committee is responsible for reviewing the diversity of the Board, reviewing the Board Diversity Policy from time to time, developing and reviewing measurable objectives for implementing the Board Diversity Policy, and monitoring the progress on achieving these measurable objectives in order to ensure that the policy remains effective. The Company will (i) disclose the biographical details of each Director and (ii) report on the implementation of the Board Diversity Policy (including whether we have achieved board diversity) in its annual corporate governance report. In particular, our Company will take opportunities to increase the proportion of female members of the Board when selecting and recommending suitable candidates for Board appointments to help enhance gender diversity in accordance with stakeholder expectations and recommended best practices.

One out of seven of our Directors will be female upon [**REDACTED**], and we have been taking and will continue to take steps to maintain that our Board will have at least one female Director after the [**REDACTED**]. Further, we have been taking, and will continue to take steps to promote gender diversity at our Board and management levels. Our board diversity policy provides that our Board should aim to increase the proportion of female members over time after the [**REDACTED**] where possible when selecting and making recommendations on suitable candidates for our Board appointments. Our Company places great importance on gender diversity, with 21.04% of our employees being female as of December 31, 2025. Our Company will (i) consider the possibility of appointing female senior management who has the necessary skills and experience; (ii) ensure that gender diversity is promoted in our Group by recruiting staff at middle to senior level; (iii) provide career development and training opportunities to our female staff whom we consider having the suitable experience, skill and knowledge of our operation and business to prepare them with the required attributes and competencies to serve as members of our Board with regards to our strategic needs and the industry in which we operate, such that they will be eligible for managerial and board-level positions in the future; and (iv) identify and select suitable female candidates to become our Board members and such candidates will be reviewed and recommended by our Nomination Committee to our Board periodically. We are of the view that the above measures will offer greater prospects for securing a pipeline of female candidates to achieve further gender diversity in our Board in the long run.

COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

We offer our executive Directors and senior management members, who are also employees of our Company, emolument in the form of fees, salaries, allowances and benefits in kind, discretionary bonuses, retirement scheme contributions and other employee benefits. Our Directors' remuneration is determined with reference to the relevant Director's experience and qualifications, level of responsibility, performance and the time devoted to our business, and the prevailing market conditions. Our independent non-executive Directors receive emolument based on their responsibilities (including being members or chairperson of Board committees).

The aggregate amount of remuneration which was paid or payable to our Directors (including fees, salaries, allowances and benefits in kind, discretionary bonuses and retirement scheme contributions) for the three financial years ended December 31, 2023, 2024 and 2025 were approximately RMB3.7 million, RMB4.5 million and RMB4.6 million, respectively.

It is estimated that the aggregate amount of remuneration (including fees, salaries, allowances and benefits in kind, discretionary bonuses and retirement scheme contributions) payable to Directors for the year ending December 31, 2026 would be approximately HK$4.0 million under arrangements currently in force.

For the three financial years ended December 31, 2023, 2024 and 2025, there were two, three and two Directors among the five highest paid individuals, respectively. The aggregate amount of remuneration (including salaries, allowance and benefits in kind, discretionary bonuses, retirement scheme contributions, termination benefits and equity-settled share-based payments) which were paid by our Group to our five highest paid individuals (excluding Directors) for the three financial years ended December 31, 2023, 2024 and 2025 were approximately RMB3.2 million, RMB1.5 million and RMB3.5 million, respectively.

During the Track Record Period, (i) no remuneration was paid to our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group, and (ii) no compensation was paid to, or receivable by, our Directors, past Directors or the five highest paid individuals for the loss of office as a director of any member of our Group or any other office in connection with the management of the affairs of any member of our Group.

During the Track Record Period, there has been no arrangement under which a Director has waived or agreed to waive any emoluments.

Except as disclosed above, no other payments have been paid, or are payable, by our Company or any of our subsidiaries to our Directors or the five highest paid individuals of our Group during the Track Record Period.

For additional information on Directors' remuneration during the Track Record Period as well as information on the five highest paid individuals, see notes 8 and 9 to the Accountants' Report.